New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies
Author: Anonim
Publsiher: Academic Press
Total Pages: 250
Release: 2020-11-01
ISBN 10: 0128167378
ISBN 13: 9780128167373
Language: EN, FR, DE, ES & NL

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies Book Review:

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies provides general updated information on the resistance of various human lymphoma/leukemia subtypes to anti-CD20 therapeutic antibodies. It discusses also the description of various targeted sensitizing agents that can reverse innate or acquired resistance when used in combination with various FDA-approved anti-CD20 antibodies. There have been a lot of reports in which the treatment with anti-CD20 antibodies for various lymphomas/leukemias has resulted in significant clinical responses; however, there have been also subsets of cancer patients who did not respond initially and several of the responding patients developed resistance to subsequent treatments with the same or different regimens. Therefore, the use of various immunosensitizing agents targeting resistant factors to reverse resistance has been considered and this book discusses each of them in depth, such as Bortexomib, Immunomodulation Agents, Obinutuzumab, Tumor Suppressors, and HDAC Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to anti-CD20 antibodies. Provides a general overview of various sensitizing agents that can work effectively when used in combination with anti-CD20 antibodies to reverse resistance Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to further antibody treatments Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field

Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Reality

Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Reality
Author: Abhishek D Garg,Patrizia Agostinis
Publsiher: Frontiers Media SA
Total Pages: 329
Release: 2016-04-29
ISBN 10: 2889198383
ISBN 13: 9782889198382
Language: EN, FR, DE, ES & NL

Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Reality Book Review:

Classically, anti-cancer therapies have always been applied with the primary aim of tumor debulking achieved through widespread induction of cancer cell death. While the role of host immune system is frequently considered as host protective in various (antigen-bearing) pathologies or infections yet in case of cancer overtime it was proposed that the host immune system either plays no role in therapeutic efficacy or plays a limited role that is therapeutically unemployable. The concept that the immune system is dispensable for the efficacy of anticancer therapies lingered on for a substantial amount of time; not only because evidence supporting the claim that anti-cancer immunity played a role were mainly contradictory, but also largely because it was considered acceptable (and sometimes still is) to test anticancer therapies in immunodeficient mice (i.e. SCID/athymic mice lacking adaptive immune system). This latter practice played a detrimental role in appreciating the role of anticancer immunity in cancer therapy. This scenario is epitomized by the fact that for a long time the very existence of cancer-associated antigens or cancer-associated ‘danger signaling’ remained controversial. However, over last several years this dogmatic view has been considerably modified. The existence of cancer-associated antigens and ‘danger signaling’ has been proven to be incontrovertible. These developments have together paved way for the establishment of the attractive concept of “immunogenic cell death” (ICD). It has been established that a restricted class of chemotherapeutics/targeted therapeutics, radiotherapy, photodynamic therapy and certain oncolytic viruses can induce a form of cancer cell death called ICD which is accompanied by spatiotemporally defined emission of danger signals. These danger signals along with other factors help cancer cells undergoing ICD to activate host innate immune cells, which in turn activate T cell-based immunity that helps eradicate live (or residual) surviving cancer cells. The emergence of ICD has been marred by some controversy. ICD has been criticized to be either experimental model or setting-specific or mostly a concept based on rodent studies that may have very limited implications for clinical application. However, in recent times it has emerged (through mainly retrospective or prognostic studies) that ICD can work in various human clinical settings hinting towards clinical applicability of ICD. However a widespread consensus on this issue is still transitional. In the current Research Topic we aimed to organize and intensify a discussion that strives to bring together the academic and clinical research community in order to provide a background to the current state-of-the-art in ICD associated bench-side research and to initiate fruitful discussions on present and future prospects of ICD translating towards the clinical, bedside reality.

Perry's The Chemotherapy Source Book

Perry's The Chemotherapy Source Book
Author: Michael C. Perry,Donald C. Doll,Carl E. Freter
Publsiher: Lippincott Williams & Wilkins
Total Pages: 848
Release: 2012-07-30
ISBN 10: 1469803437
ISBN 13: 9781469803432
Language: EN, FR, DE, ES & NL

Perry's The Chemotherapy Source Book Book Review:

Perry’s The Chemotherapy Source Book, now in its fifth edition, provides information on the choice of chemotherapeutic agents, the use of combination chemotherapy, and the toxicity of individual drugs. Organized by site, this is the only book of its kind to focus strictly on the clinical practice of chemotherapy, and is meant to serve as a “one-stop shop” for information on choice of chemotherapeutic agents, treatment outlines, grading of side effects, and dose modification.

Yonsei Medical Journal

Yonsei Medical Journal
Author: Anonim
Publsiher: Anonim
Total Pages: 329
Release: 2007
ISBN 10:
ISBN 13: MINN:31951P01070862B
Language: EN, FR, DE, ES & NL

Yonsei Medical Journal Book Review:

Clinical Radiation Oncology

Clinical Radiation Oncology
Author: Leonard L. Gunderson,Joel E. Tepper
Publsiher: Elsevier Health Sciences
Total Pages: 1827
Release: 2007
ISBN 10: 0443068402
ISBN 13: 9780443068409
Language: EN, FR, DE, ES & NL

Clinical Radiation Oncology Book Review:

First Prize winner, Oncology Book Category, British Medical Association 2012 Medical Book Competition Deepen your knowledge with a comprehensive, clinical approach to the scientific foundations of radiation oncology and general oncology as well as state-of-the-art techniques and modalities. Implement a multidisciplinary, "team care" approach to providing intricate treatment plans for patients, often in conjunction with medical oncologists, and surgeons. Broaden your understanding of the basic biology of the disease processes. Examine the therapeutic management of specific disease sites based on single-modality and combined-modality approaches. Quickly and easily find critical information thanks to an easily accessible, full-color design with over 800 color figures that clearly depict treatment techniques. Get broad multimodality perspectives and unique insights from a diverse team of respected editors and contributors -many of whom are new to this edition - affiliated with institutions across North America and internationally Access the fully searchable text anywhere, anytime at www.expertconsult.com, along with references, additional images and tables, video clips and more! Stay current with comprehensive updates throughout that include a new chapter on survivorship issues, and additional video clips on treatments such as prostate and penile cancer brachytherapy. Improve outcomes by providing the most effective treatment for each patient with expanded coverage of new modalities and treatment regimens. Understand and comply with the latest staging guidelines. Drs. Gunderson and Tepper give you quick access to all the clinical tools you need to master the newest techniques and modalities in radiation oncology.

Clinical Radiation Oncology E-Book

Clinical Radiation Oncology E-Book
Author: Leonard L. Gunderson,Joel E. Tepper
Publsiher: Elsevier Health Sciences
Total Pages: 1660
Release: 2011-09-16
ISBN 10: 1455726036
ISBN 13: 9781455726035
Language: EN, FR, DE, ES & NL

Clinical Radiation Oncology E-Book Book Review:

With thorough updates throughout, Clinical Radiation Oncology provides the most comprehensive, authoritative, and up-to-date information available for treating patients with cancer. From a multidisciplinary perspective, this new edition, edited by Drs. Leonard L. Gunderson and Joel E. Tepper, examines the therapeutic management of specific disease sites based on both single-modality and combined-modality approaches - providing you with the well-rounded, cutting-edge guidance you need to offer the most effective treatments. A consistent chapter format, full-color design, and access to the full text at www.expertconsult.com make reference fast and easy. It is an ideal resource for mastering the latest, most effective techniques and modalities! Deepen your knowledge with a comprehensive, clinical approach to the scientific foundations of radiation oncology and general oncology as well as state-of-the-art techniques and modalities. Implement a multidisciplinary, "team care" approach to providing intricate treatment plans for patients, often in conjunction with medical oncologists, and surgeons. Broaden your understanding of the basic biology of the disease processes. Examine the therapeutic management of specific disease sites based on single-modality and combined-modality approaches. Quickly and easily find critical information thanks to an easily accessible, full-color design with over 800 color figures that clearly depict treatment techniques. Get broad multimodality perspectives and unique insights from a diverse team of respected editors and contributors –many of whom are new to this edition – affiliated with institutions across North America and internationally Access the fully searchable text anywhere, anytime at www.expertconsult.com, along with references, additional images and tables, video clips and more! Stay current with comprehensive updates throughout that include a new chapter on survivorship issues, and additional video clips on treatments such as prostate and penile cancer brachytherapy. Improve outcomes by providing the most effective treatment for each patient with expanded coverage of new modalities and treatment regimens. Understand and comply with the latest staging guidelines.

Lymphoma: Pathology, Diagnosis and Treatment

Lymphoma: Pathology, Diagnosis and Treatment
Author: Robert Marcus,John W. Sweetenham,Michael E. Williams
Publsiher: Cambridge University Press
Total Pages: 277
Release: 2007-06-21
ISBN 10: 9780521865449
ISBN 13: 0521865441
Language: EN, FR, DE, ES & NL

Lymphoma: Pathology, Diagnosis and Treatment Book Review:

Places the major advances which have occurred in the area of lymphoma into the context of daily clinical practice.

Pediatric Lymphomas

Pediatric Lymphomas
Author: Howard J. Weinstein,Melissa M. Hudson,Michael P. Link
Publsiher: Springer Science & Business Media
Total Pages: 292
Release: 2007-01-20
ISBN 10: 354068753X
ISBN 13: 9783540687535
Language: EN, FR, DE, ES & NL

Pediatric Lymphomas Book Review:

This is a comprehensive textbook of Hodgkin's and non-Hodgkin's lymphomas written by leaders in the field of childhood lymphomas. It includes clinical, pathologic and molecular biology of each subtype of lymphoma. The pathology chapters are comprehensive and include excellent photographs. The book is at the level of subspecialists in pediatric hematology and oncology, radiation oncology, pediatric surgery and hematopathology.

Novel Therapeutics for Rare Lymphomas

Novel Therapeutics for Rare Lymphomas
Author: Christopher Dittus
Publsiher: Springer Nature
Total Pages: 253
Release: 2019-10-23
ISBN 10: 3030256103
ISBN 13: 9783030256104
Language: EN, FR, DE, ES & NL

Novel Therapeutics for Rare Lymphomas Book Review:

This comprehensive volume reviews the clinical presentation, diagnosis, and treatment approach to rare lymphomas. There is particular emphasis placed on new diagnostic approaches, novel chemotherapy combinations, and treatment modalities with novel therapeutics. It highlights research advances in a group of diseases that are often overlooked, and serves as a single repository of information on the most recent advances in targeted small molecule inhibitors, monoclonal antibodies, immunotherapy, and CAR-T therapy as they pertain to rare types of lymphoma. Written for practicing oncologists, hematologists, fellows, and residents, Novel Therapeutics for Rare Lymphomas covers rare subtypes of lymphoma, including indolent and aggressive T-cell lymphomas and B-cell lymphomas.

The Journal of Immunology

The Journal of Immunology
Author: Anonim
Publsiher: Anonim
Total Pages: 329
Release: 2007
ISBN 10:
ISBN 13: UIUC:30112083160074
Language: EN, FR, DE, ES & NL

The Journal of Immunology Book Review:

Annual Meeting Proceedings

Annual Meeting Proceedings
Author: American Society of Clinical Oncology. Meeting
Publsiher: Anonim
Total Pages: 329
Release: 2007
ISBN 10:
ISBN 13: CHI:77004183
Language: EN, FR, DE, ES & NL

Annual Meeting Proceedings Book Review:

Dissertation Abstracts International

Dissertation Abstracts International
Author: Anonim
Publsiher: Anonim
Total Pages: 329
Release: 2008
ISBN 10:
ISBN 13: STANFORD:36105131549656
Language: EN, FR, DE, ES & NL

Dissertation Abstracts International Book Review:

Non-Myeloablative Allogeneic Transplantation

Non-Myeloablative Allogeneic Transplantation
Author: Asad Bashey,Edward D. Ball
Publsiher: Springer Science & Business Media
Total Pages: 216
Release: 2002-02-28
ISBN 10: 9780792376460
ISBN 13: 0792376463
Language: EN, FR, DE, ES & NL

Non-Myeloablative Allogeneic Transplantation Book Review:

Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years. This approach uses non-cytotoxic or reduced-intensity cytotoxic therapy to prepare patients for allografting of hematopoietic stem cells and lymphocytes. It has the potential to deliver the potent anti-tumor immunotherapy and bone marrow replacement capacity of allogeneic stem cell transplantation to patients with reduced treatment-related morbidity and mortality. It may also enable allogeneic transplantation in patients who would be considered ineligible for conventional transplants because of co-morbidity or advanced age. However, this approach may necessitate more careful monitoring of post-transplant chimerism and malignant disease-status than is usual with conventional allografting. There is also controversy regarding the best preparative regimen and graft-versus-host disease prophylaxis to use.

Antiphospholipid Syndrome in Systemic Autoimmune Diseases

Antiphospholipid Syndrome in Systemic Autoimmune Diseases
Author: R. Cervera,Ricard Cervera
Publsiher: Elsevier
Total Pages: 266
Release: 2009-04-01
ISBN 10: 9780080932347
ISBN 13: 0080932347
Language: EN, FR, DE, ES & NL

Antiphospholipid Syndrome in Systemic Autoimmune Diseases Book Review:

Antiphospholipid syndrome is an autoimmune disease that causes abnormal blood clots. It is now recognized as a major cause of common conditions, including stroke, heart attack, miscarriage, epilepsy and memory loss and as such is gaining recognition in all branches of medicine, from obstetrics to cardiology, from psychiatry to orthopedics. This book provides an overview of our current understanding of this major disease. It includes the latest information on the new pathogenetic mechanisms involved as well as clinical manifestations in both “the thrombotic and “non-thrombotic manifestations of this important disease. * Comprehensive review of this major disease * Includes information on treatment options available

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Author: E. Campo,N. L. Harris,S. A. Pileri,E. S. Jaffe,H. Stein,J. Thiele
Publsiher: IARC Who Classification of Tum
Total Pages: 586
Release: 2017-09-18
ISBN 10: 9789283244943
ISBN 13: 928324494X
Language: EN, FR, DE, ES & NL

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Book Review:

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues is a Revised Fourth Edition of the WHO series on histological and genetic typing of human tumours. This authoritative, concise reference provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. Diagnostic criteria, pathological features, and associated genetic alterations are described in a strictly disease-oriented manner. Sections on all recognized neoplasms and their variants further include new ICD-O codes, epidemiology, clinical features, macroscopy, prognosis, and predictive factors. This classification, prepared by 132 authors from 23 countries, contains about 1300 color images and tables and more than 4500 references.

Vaccines E-Book

Vaccines E-Book
Author: Stanley A. Plotkin,Walter Orenstein,Paul A. Offit,Kathryn M. Edwards
Publsiher: Elsevier Health Sciences
Total Pages: 1376
Release: 2017-04-07
ISBN 10: 0323393012
ISBN 13: 9780323393010
Language: EN, FR, DE, ES & NL

Vaccines E-Book Book Review:

From the development of each vaccine to its use in reducing disease, Plotkin’s Vaccines, 7th Edition, provides the expert information you need to provide optimal care to your patients. This award-winning text offers a complete understanding of each disease, as well as the latest knowledge of both existing vaccines and those currently in research and development. Described by Bill Gates as "an indispensable guide to the enhancement of the well-being of our world," Plotkin’s Vaccines is a must-have reference for current, authoritative information in this fast-moving field. Includes complete information for each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, epidemiology, and public health and regulatory issues – plus complete information for each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies. Analyzes the cost-benefit and cost-effectiveness of different vaccine options. Helps you clearly visualize concepts and objective data through an abundance of tables and figures. Covers the new oral cholera and zoster vaccines, as well as newly licensed meningococcal group B vaccines and a newly licensed dengue vaccine. Brings you up to date on successful human trials of Ebola vaccines, an enterovirus 71 vaccine licensed in China, and new recommendations and changes to polio vaccines. Features a new chapter on maternal immunization.

Therapeutic Strategies in Cancer Biology and Pathology

Therapeutic Strategies in Cancer Biology and Pathology
Author: Gajanan V. Sherbet
Publsiher: Elsevier
Total Pages: 310
Release: 2013-07-26
ISBN 10: 0124165907
ISBN 13: 9780124165908
Language: EN, FR, DE, ES & NL

Therapeutic Strategies in Cancer Biology and Pathology Book Review:

Currently, intensive effort is being directed toward the identification of molecular targets that can provide approaches to the development of novel therapeutic strategies in cancer management. This book focuses on metastasis-associated genes, metastasis promoter and suppressor genes, which relate specifically to behavioral alterations of cancer cells in epithelial mesenchymal transition, cancer stem cell maintenance and propagation, and to the acquisition of invasive and metastasis faculty. The function of these genes has implications for cell cycle regulation and cell proliferation and so constitute an essential element in cancer growth and dissemination. The emphasis in this book is on how appropriate these genes are as molecular targets and how practicable are the constituents of their signal transduction systems as potential candidates and how accessible they are to targeted therapy. Written in a straightforward and clear style with background information supporting the new research, this book will be useful for students and researchers in cancer therapies. Identifies molecular targets and their accessibility for therapeutic intervention Provides information on biological features of tumor development and dissemination Background information provided for each topic

Journal of the National Cancer Institute

Journal of the National Cancer Institute
Author: Anonim
Publsiher: Anonim
Total Pages: 329
Release: 2002
ISBN 10:
ISBN 13: NWU:35558004778466
Language: EN, FR, DE, ES & NL

Journal of the National Cancer Institute Book Review:

"Summaries of papers" contained in the journal accompany each issue, 19--

Autoimmune Bullous Diseases

Autoimmune Bullous Diseases
Author: Müzeyyen Gönül,Seray Çakmak
Publsiher: BoD – Books on Demand
Total Pages: 256
Release: 2018-05-09
ISBN 10: 1789230268
ISBN 13: 9781789230260
Language: EN, FR, DE, ES & NL

Autoimmune Bullous Diseases Book Review:

Autoimmune bullous diseases are a group of rare skin diseases characterized by intraepidermal and subepidermal bullae formations due to autoantibodies directed against the structural proteins of the epidermis or the dermal-epidermal junction. Early and correct diagnosis and adequate treatment of autoimmune bullous diseases are important as they cause morbidity and mortality in the affected patients. This book, which gives detailed information about autoimmune bullous diseases, has two sections and nine chapters with sixteen contributing authors. The first section describes the structure and tasks of desmosomes and basement membrane zone, which consist of the major antigens of skin integrity targeted by autoantibodies. The second section is about the epidemiology, etiopathogenesis, mucocutaneous, histopathologic and laboratory findings, and therapy of autoimmune bullous diseases.

Nanotheranostics for Cancer Applications

Nanotheranostics for Cancer Applications
Author: Prakash Rai,Stephanie A. Morris
Publsiher: Springer
Total Pages: 480
Release: 2018-11-12
ISBN 10: 3030017753
ISBN 13: 9783030017750
Language: EN, FR, DE, ES & NL

Nanotheranostics for Cancer Applications Book Review:

This book is the first to focus specifically on cancer nanotheranostics. Each of the chapters that make up this comprehensive volume is authored by a researcher, clinician, or regulatory agency member known for their expertise in this field. Theranostics, the technology to simultaneously diagnose and treat a disease, is a nascent field that is growing rapidly in this era of personalized medicine. As the need for cost-effective disease diagnosis grows, drug delivery systems that can act as multifunctional carriers for imaging contrast and therapy agents could provide unique breakthroughs in oncology. Nanotechnology has enabled the development of smart theranostic platforms that can concurrently diagnose disease, start primary treatment, monitor response and initiate secondary treatments if required. In oncology, chemotherapeutics have been routinely used. Some drugs have proven effective but all carry risks of adverse side effects. There is growing interest in using remotely triggered drug delivery systems to limit cytotoxicity in the diseased area. This book reviews the use of theranostic nanoparticles for cancer applications over the past decade. First, it briefly discusses the challenges and limitations of conventional cancer treatments, and presents an overview of the use of nanotechnology in treating cancer. These introductory chapters are followed by those exploring cancer diagnosis and a myriad of delivery methods for nanotherapeutics. The book also addresses multifunctional platforms, treatment monitoring, and regulatory considerations. As a whole, the book aims to briefly summarize the development and clinical potential of various nanotheranostics for cancer applications, and to delineate the challenges that must be overcome for successful clinical development and implementation of such cancer theranostics.